For example, blocking PD-1/PD-L1 is an attractive cancer immunotherapy strategy, and PD-L1 immunohistochemistry is currently widely used to predict the efficacy of melanoma treatment response (22–24). The gene discussed is PDCD1; the disease is melanoma.